Annual report
3341.TEDINET S100W6B8
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥360.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥340.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥299.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥279.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥6.2bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥9.1bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥6.9bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.4bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.9bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥197.1bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥195.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥178.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥186.3bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥138.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥136.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥58.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥49.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥27.5bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥25.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥32.9bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥9.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥10.0bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥9.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥713m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥17.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥46.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.56 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,978.13 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,950.44 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,888.17 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,763.34 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,663.01 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 30.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 6,063 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 5,864 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 5,689 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 5,552 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 5,221 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥315.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥298.0bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥275.3bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥259.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥233.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥7.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.6bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.9bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥5.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥3.0bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥3.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥157.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥155.7bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥148.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥140.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥145.5bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥112.9bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥111.9bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥44.3bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥43.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥41.5bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥39.2bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥37.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥19.7bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥18.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥43.94 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥99.76 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥105.35 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥77.25 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥116.69 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥25 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,482.24 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,462.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,388.25 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,308.05 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,255.8 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 28.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.1% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 31,048,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 31,048,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 32,048,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,798 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4,642 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,587 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 4,458 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,034 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 70
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥788m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥13.0bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6.6bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 4752 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥322.0bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥322.0bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥118.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥13.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥119m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥131m |
| Medical Professional Staffing And Placement Businessreportable segment | employees | at 2025-03-31 | 321 pure |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.2bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥185m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2025-03-31 | ¥5.4bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥937m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.3bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | employees | at 2025-03-31 | 838 pure |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥40.2bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥27.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2025-03-31 | ¥70.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥630m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥9.1bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥6.9bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥373.5bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥360.5bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| —segment total | segment assets | at 2025-03-31 | ¥194.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥13.8bn |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥780m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥12.9bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥3.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥7.2bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥8.9bn |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥302.8bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥115.7bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥15.2bn |
| Medical Professional Staffing And Placement Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥83m |
| Medical Professional Staffing And Placement Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥147m |
| Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.9bn |
| Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥111m |
| Medical Professional Staffing And Placement Businessreportable segment | segment assets | at 2024-03-31 | ¥5.0bn |
| Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥937m |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥40.4bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥27.6bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.8bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment assets | at 2024-03-31 | ¥71.1bn |
| Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥250m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥353.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥340.3bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12.9bn |
| —segment total | segment assets | at 2024-03-31 | ¥191.7bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥16.4bn |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 4646 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,575
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 200646 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 309901 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 57900 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0551 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0104 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2008 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0861 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0002 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.6474 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 6648600 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.2217 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 5840000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1948 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 4800000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.1601 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 1365400 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0455 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 965200 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0322 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 800000 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0267 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 595449 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0199 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 538600 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0180 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 222593 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0074 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 172900 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0058 | |
| Number of shares held | CurrentYearInstant | 21948742 | |
| Shareholding ratio | CurrentYearInstant | 0.7320 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 1061700 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 29928400 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 299284 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 57900 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 31048000 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 299284 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 1061700 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 1061700 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0342 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 1061700 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 1061700 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0342 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |